| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2124449 | European Journal of Cancer | 2008 | 11 Pages |
Abstract
ILC is a distinct entity of breast cancer that responds well to adjuvant HT. These data add important clinical information for assessing the long-term benefits of adjuvant HT use in ILC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Emad A. Rakha, Maysa E. El-Sayed, Desmond G. Powe, Andrew R. Green, Hany Habashy, Matthew J. Grainge, John F.R. Robertson, Roger Blamey, Julia Gee, Robert I. Nicholson, Andrew H.S. Lee, Ian O. Ellis,